Clifford Chance has advised Ping An Good Doctor, China’s largest online healthcare platform, on its $1.12 billion initial public offering in Hong Kong, with Davis Polk & Wardwell advising the underwriters, which included Citigroup and JPMorgan.

The issuer is backed by Ping An Insurance, which turned to DLA Piper for advice. Chinese firms Haiwen & Partners and Grandall Law Firm acted as legal advisors to the issuer and underwriters, respectively, on PRC law. Offshore firm Maples and Calder was also involved in the deal, advising the issuer on Cayman Islands law.

Ping An Good Doctor has a nationwide network of healthcare service providers covering 3,100 hospitals, 1,100 health check-up centers, 500 dental clinics and 7,500 pharmacy outlets.

Its debut comes at a time when Hong Kong is implementing new rules to attract more tech and biotech IPOs to the city. Hong Kong is set to see a slew of blockbuster tech IPOs over the coming months, including smartphone and smart device maker Xiaomi. Clifford Chance and Maples and Calder are also involved in the upcoming Xiaomi IPO, advising the joint sponsors and the issuer, respectively.

The Clifford Chance team was led by China co-managing partner Tim Wang and Hong Kong-based partners Amy Lo and Fang Liu, while the Davis Polk team was led by Hong Kong-based partners Bonnie Chan and Li He.

Shanghai-based senior partner Roy Chan and Hong Kong-based partner Christina Loh led the deal for DLA Piper.

Related Articles

华润饮料拟赴港上市(ZH/EN)

by Charlie Wu 吴卓言 |

华润饮料(控股)有限公司(华润饮料)已于4月22日向香港联合交易所递交上市申请。自2022年以来,华润饮料几度被传筹备推动华润饮料赴港上市,据彭博报道,该项目募资规模或达 10 亿美元。

竞天公诚、金杜等助力茶百道登陆香港联交所(ZH/EN)

by Charlie Wu 吴卓言 |

4月23日,四川百茶百道实业股份有限公司(茶百道)在香港联合交易所主板挂牌上市,募资额达3.3亿美元。

高伟绅、司力达牵头赛生药业11.3亿美元私有化交易(ZH/EN)

近日,私募股权公司德福资本对港交所上市公司赛生药业提出私有化邀约。本次私有化交易通过协议安排方式实施,实施所需的现金总额约为 87.9 亿港元(约 为11.3 亿美元)。